BIOTRAK™ REAL-TIME VIABLE PARTICLE COUNTER - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

BIOTRAK™ REAL-TIME VIABLE PARTICLE COUNTER

A real-time viable particle counter such as the TSI BioTrak™ detector can continuously monitor an aseptic process for airborne viable particles, and per the current GMP guidance, monitor total particle counts simultaneously using an existing single particle monitoring probe. Data is logged and alarms generated in real-time using a Facility Monitoring System. No need to intervene and cleanup following a plate change or load growth media into the isolator, no need to add additional interfaces. If there is a microbiological excursion, everyone will know right away..

In a single portable instrument the TSI BioTrak™ Real-time viable particle detector counts airborne particles compliant to ISO 21501-4and has a 28.3 lpm sample flow rate. It then analyzes each particle for viability, finally it collects all optically analyzed particles on a collection filter to enable laboratory based speciation analysis. BioTrak™ – the real-time viable particle counter that delivers airborne viable particle count data you can trust, moving you towards real-time quality assurance and process control.

Contact TSI (www.tsi.com) today to arrange an evaluation and find out more about the many immediate use applications the BioTrak detector has to offer. Gain a competitive advantage today, the potential benefits this technology has to offer are too great to ignore.

Further information on Biotrak visit: www.tsi.com/biotrak-9510 or E-Mail: emea.tsi@tsi.com

About TSI Incorporated

TSI Incorporated serves a global market by investigating, identifying and solving measurement problems. As an industry leader in the design and production of precision instruments, TSI partners with research institutions and customers around the world to set the standard for measurements relating to aerosol science, air flow, health and safety, indoor air quality, fluid dynamics and biohazard detection.

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
FindPharma Custom Search

Click here